Anthony Mutsaers

Anthony Mutsaers

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2013 in Bone
Verified
Journal Article
Closed access
AMAnthony Mutsaers
Anthony Mutsaers
ANAlvin J.M. Ng
Alvin J.M. Ng
EBEmma K. Baker
Emma K. Baker
MRMegan R. Russell
Megan R. Russell
ACAlistair M. Chalk
Alistair M. Chalk
CWCarl R. Walkley
Carl R. Walkley

12 April 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAmohamed aborig
mohamed aborig
PMPaul Malik
Paul Malik
SNShruti Nambiar
Shruti Nambiar
PCPierre Chelle
Pierre Chelle
JDJohnson Darko
Johnson Darko
SWShawn Wettig
Shawn Wettig
Gold nanoparticles (AuNPs) are a focus of growing medical research applications due to their unique chemical, electrical and optical properties. Because of uncertain toxicity, “green” synthesis methods are emerging, using plant extracts to improve biological and environmental compatibility. Here we explore the biodistribution of green AuNPs in mice and prepare a physiologically-based pharmacokinetic (PBPK) model to guide interspecies extrapolation. Monodisperse AuNPs were synthesized and capped with epigallocatechin gallate (EGCG) and curcumin. 64 CD-1 mice received the AuNPs by intraperitoneal injection. To assess biodistribution, groups of six mice were sacrificed at 1, 7, 14, 28 and 56 days, and their organs were analyzed for gold content using inductively coupled plasma mass spectrometry (ICP-MS). A physiologically-based pharmacokinetic (PBPK) model was developed to describe the biodistribution data in mice. To assess the potential for interspecies extrapolation, organism-specific parameters in the model were adapted to represent rats, and the rat PBPK model was subsequently evaluated with PK data for citrate-capped AuNPs from literature. The liver and spleen displayed strong uptake, and the PBPK model suggested that extravasation and phagocytosis were key drivers. Organ predictions following interspecies extrapolation were successful for rats receiving citrate-capped AuNPs. This work lays the foundation for the pre-clinical extrapolation of the pharmacokinetics of AuNPs from mice to larger species.

22 March 2018 in Applied Nanoscience
Verified
Journal Article
Closed access
PDF file
SNShruti Nambiar
Shruti Nambiar
EOErnest Osei
Ernest Osei
AFAndre Fleck
Andre Fleck
JDJohnson Darko
Johnson Darko
AMAnthony Mutsaers
Anthony Mutsaers
SWShawn Wettig
Shawn Wettig

15 June 2002 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Closed access
AMAnthony Mutsaers
Anthony Mutsaers
NGNita W. Glickman
Nita W. Glickman
DDDennis B. DeNicola
Dennis B. DeNicola
WWWilliam R. Widmer
William R. Widmer
PBPatty L. Bonney
Patty L. Bonney
DKDeborah W. Knapp
Deborah W. Knapp
Objective—To evaluate the antitumor and toxic effects of treatment with doxorubicin combined with piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Design—Nonrandomized clinical trial. Animals—75 dogs with multicentric lymphoma. Procedure—33 dogs were treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h); results were compared with a historical control group of 42 dogs treated with doxorubicin (30 mg/m2, IV, q 21 d, for 3 doses) alone. Results—The percentages of dogs that had remission with doxorubicin-piroxicam treatment (79%) or doxorubicin treatment alone (74%) were not significantly different. Median duration of first remission was 130 days with doxorubicin-piroxicam and 147 days with doxorubicin alone; these values were not significantly different. Severe toxicosis was observed in 22% of dogs treated with doxorubicin-piroxicam and 17% of dogs treated with doxorubicin alone. Conclusions and Clinical Relevance—Both treatment protocols were efficacious and well tolerated. The doxorubicin-piroxicam treatment was no more effective regarding response rate, remission duration, or survival duration, compared with the control group treated with doxorubicin alone. (J Am Vet Med Assoc 2002;220:1813–1817)

4 October 2012 in Clinical Sarcoma Research
Verified
Journal Article
Open access
PDF file
ANAlvin Jm Ng
Alvin Jm Ng
AMAnthony Mutsaers
Anthony Mutsaers
EBEmma K Baker
Emma K Baker
CWCarl R Walkley
Carl R Walkley
Osteosarcoma is the most common form of bone cancer. Pivotal insight into the genes involved in human osteosarcoma has been provided by the study of rare familial cancer predisposition syndromes. Three kindreds stand out as predisposing to the development of osteosarcoma: Li-Fraumeni syndrome, familial retinoblastoma and RecQ helicase disorders, which include Rothmund-Thomson Syndrome in particular. These disorders have highlighted the important roles ofP53andRBrespectively, in the development of osteosarcoma. The association of OS withRECQL4mutations is apparent but the relevance of this to OS is uncertain as mutations inRECQL4are not found in sporadic OS. Application of the knowledge or mutations ofP53andRBin familial and sporadic OS has enabled the development of tractable, highly penetrant murine models of OS. These models share many of the cardinal features associated with human osteosarcoma including, importantly, a high incidence of spontaneous metastasis. The recent development of these models has been a significant advance for efforts to improve our understanding of the genetics of human OS and, more critically, to provide a high-throughput genetically modifiable platform for preclinical evaluation of new therapeutics.